Get the latest news, insights, and market updates on MCRB (Seres Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherape Aug 6, 2025 - $MCRB
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:30 a.m. ET to discuss second quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 3641971. To join the live webcast Jul 22, 2025 - $MCRB
Seres Therapeutics Announces Leadership Transition
Thomas DesRosier and Marella Thorell, accomplished biopharma executives, appointed co-CEOs; Eric Shaff stepping down as CEO and will remain a Director on the Seres Board Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure additional capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates CAMBRIDGE, Mass., July 22, 2025 (GLOBE NE Jul 22, 2025 - $MCRB
Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities
The human microbiome market is projected to expand at a CAGR of 20.42%, growing from $941.215 million in 2025 to $2.38 billion by 2030. This growth is driven by rising lifestyle diseases, an aging populace, and biomedical tech advances. Challenges include low awareness and government restrictions. The comprehensive report explores market trends, technological advancements, and regulatory impacts, featuring key players like Seres Therapeutics and Ferring Pharmaceuticals. It's essential for busine Jun 19, 2025 - $MCRB
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT)CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase 1b study in a poster session at the 2025 A May 27, 2025 - $MCRB
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple